A Treatment Targeting KRAS Mutations in Lung Cancer Finally Gets Underway

The newly developed KRAS inhibitor "AMG 510," according to results presented at the 2019 World Lung Conference from a phase-1 trial, achieved tumor control in almost all advanced non-small cell lung cancer patients.
The KRAS protein is important in normal cell growth. Produced by the KRAS gene, it transmits external signals to the cell nucleus. When it undergoes mutation , the cell grows "aggressively." Mutated KRAS continuously sends a "proliferate" command even without external signals. KRAS is also responsible for targeted drug resistance in cancer.

KRAS mutations frequently occur in exon 1 at codon 12 (80%) and 13 (15%), and in exon 2 at codon 61. The most common are Gly12AIa, Gly12Asp, Gly12Arg, Gly12Cys, Gly12Ser, Gly12Val and Gly13Asp.
An Effective KRAS-Targeting Treatment Would Be a Major Lung Cancer Milestone
The most striking study at the World Conference on Lung Cancer, starting on 7 September 2019 in Barcelona, concerned a mutation in KRAS previously of unclear clinical significance, the KRAS G12C variant , targeted by the anticancer molecule AMG 510.
With AMG 510, treatment responses among 23 patients were:
- 11 partial responses,
- 11 stable disease cases,
- 1 progression.
From phase-1 to phase-2, among 13 patients, 7 (54%) achieved partial response and 6 stable disease.
Dr. Ramaswamy Govindan of Washington University presented initial results, reporting a favorable safety profile for AMG 150 because no dose-limiting or cumulative side effects were observed.
"AMG 510 showed promising antitumor activity even in early trials among KRAS G12C mutation-positive non-small cell lung cancer patients. Following the phase-I combination study, a phase-II monotherapy study continues," he said.
KRAS G12C mutations occur in approximately 13% of non-small cell lung cancers, with no approved treatment targeting this alteration to date. AMG 510 is a first-generation small-molecule KRAS inhibitor that specifically and irreversibly blocks KRAS.
KRAS G12C also occurs in 3-5% of colorectal and appendiceal cancers and 1% to 3% of other tumors.

Study Details
The study included patients whose disease progressed during or after standard treatments, with no active brain metastasis , and advanced non-small cell lung cancer (KHDAK). Initial data were reported at the 2019 ASCO Annual Meeting.
- Researchers enrolled 34 patients with KHDAK among 76 total patients.
- The 34 patients had a median age of 67,5, with 18 women.
- All but 3 had ECOG 0 or 1 performance status , and all but 5 had previously received a median of 3.5 systemic cancer treatments.
- Three-quarters had side effects of any grade, and 12 (35.3%) had treatment-related effects, mostly mild. No grade 4 or fatal treatment-related effects occurred, and no patient discontinued because of them. The most common were diarrhea (4 patients) and nausea (2 patients); grade 3 effects were diarrhea in 2 and anemia in 1.
- Of 11 patients with objective responses, 10 first responded within approximately 5 weeks. Median treatment duration was 15.1 weeks in responders and, among 11 with stable disease, 10 weeks.
In conclusion, AMG 510 appears highly effective with acceptable side effects in this small trial of KRAS G12C-positive lung cancer. Larger studies will clarify how diverse KRAS mutations affect AMG 510, as well as resistance and co-occurring mutations.
Sources
Phase 1 study of safety, tolerability, PK and efficacy of AMG 510, a novel KRASG12C inhibitor, evaluated in NSCLC.
IASLC 20th World Conference on Lung Cancer; September 7-10, 2019; Barcelona, Spain. Abstract OA02.02.
Was this article helpful?
Your feedback helps us improve our content.





Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.